首页 > 抗体蛋白 > 抗体
PerCP/Cyanine5.5 anti-mouse CD25 Antibody
产品名称:
PerCP/Cyanine5.5 anti-mouse CD25 Antibody
产品类别:
抗体
产品编号:
102029
产品应用:
102029
[价格]
规格 价格 库存
25µg ¥ 1666 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902).?For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered.?

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  2. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  3. Yu Y, et al. 2022. iScience. 25:105004. PubMed
  4. Wang D, et al. 2018. Immunity. 48:659. PubMed
  5. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  6. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  7. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  8. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  9. She L, et al. 2021. JCI Insight. 6:e143509. PubMed
  10. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  11. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  12. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  13. Emmerson A, et al. 2018. J Clin Invest. 128:3088. PubMed
  14. Toubal A, et al. 2020. Nat Commun. 3755:11. PubMed
  15. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  16. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  17. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  18. Li H, et al. 2020. Nature. 584:274. PubMed
  19. K?lin S et al. 2017. Cell metabolism. 26(3):475-492 . PubMed
  20. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  21. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  22. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  23. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  24. Srinivasan A, et al. 2021. BMC Immunol. 22:46. PubMed
  25. Han MG, et al. 2022. Cancers (Basel). 14:. PubMed
  26. Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed
  27. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  28. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  29. Piotrowski AF, et al. 2018. Oncoimmunology. 7:e1445951. PubMed
  30. Serr I, et al. 2016. Nat Commun. 7:10991. PubMed
  31. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
RRID
AB_893291 (BioLegend Cat. No. 102029) AB_893288 (BioLegend Cat. No. 102030)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J?Biol?Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp?Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J?Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线